Formats: On-Demand Video, DVD, or PDF Transcript
Price: $197
Originally presented August 31, 2011

By now you’ve heard that the Federal Circuit has rejected the finding by the Southern District of New York Court in Myriad that could have rendered invalid all patents claiming isolated forms of naturally occurring DNA molecules. Specifically, the Supreme Court has drawn a line between compositions that, even if combined or altered in a manner not found in nature, have similar characteristics as in nature, and compositions that human intervention has given “markedly different” or “distinctive” characteristics. The opinion concludes that the claimed DNA molecules meet this test.

Attorney Kevin E. Noonan, PhD, of McDonnell Boehnen Hulbert & Berghoff LLP, notes that the Federal Circuit rendered a “fractured” decision in the case. That means it will likely end up at the Supreme Court, and also leaves plenty of open questions and room for interpretation in the meantime. What does it all mean for TTOs and university researchers with gene-based innovations, in terms of both patenting and licensing?

Join Mr. Noonan for a one-hour webinar that will deeply analyze the Court’s decision and discuss how the “fractured” opinion affects your university and its relevant IP. He’ll discuss :

• Patentability of composition of matter claims (where the Court reversed the District Court’s finding that “isolated DNA” was not patent-eligible under the “products of nature” exception)
• Impact on method claims – both diagnostic methods and screening method claims
• The decision’s creation of a new categorical rule of patent-ineligibility
• Rejection of the “magic microscope” analysis by the government
• Likely outcome of future appeals
• Impact on patent prosecution decisions and claim drafting
• “isolation” vs. “purification” – what’s the difference?

Your Expert Presenter:

Kevin E. Noonan, PhD, is a Partner with McDonnell Boehnen Hulbert & Berghoff LLP and has extensive experience in biotechnology and the chemical arts. Dr. Noonan brings more than 10 years of experience as a molecular biologist working on high-technology problems to his legal work. He has wide experience in all aspects of patent prosecution, interferences, litigation, and client counseling on validity, infringement, and patenting strategy matters. He represents pharmaceutical and biotechnology companies both large and small, and he is particularly experienced in representing university clients in both patent prosecution and licensing.

Our Guarantee of Quality and Value
We stand 100% behind the quality and value of our distance learning programs . If you are dissatisfied, simply let us know and we will send you an immediate refund — no questions asked.

CLE Credits
We submit CLE applications in your state (excluding IL, LA, NJ, NY, PA) for an additional $50. Approval times vary per state. Application is not a guarantee of approval.

CLP Credits
All Technology Transfer Tactics’ professional development courses and designated educational offerings on the topics of licensing, technology transfer, and technology commercialization at Technology Transfer Tactics’ conferences or meetings are eligible for CLP continuing education (CE) credits for certification renewal.

Ordering Options
Choose from a variety of options: DVD, Online Video, or a PDF transcript of the session — all including the original program materials.

Click here to download an order form that you can print and send at a later time.